Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP11B1 | P15538 | 1/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.38 |
| ▸ | PARP1 | P09874 | 1/20 | 0.37 |
| ▸ | NPC1 | O15118 | 2/20 | 0.36 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.36 |
| ▸ | RAB9A | P51151 | 2/20 | 0.36 |
| ▸ | NFKB2 | Q00653 | 2/20 | 0.36 |
| ▸ | RELA | Q04206 | 2/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | TRPV6 | Q9H1D0 | 1/20 | 0.33 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.33 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.32 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.32 |
| ▸ | P4HTM | Q9NXG6 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4590967 | 0.87 | CYP11B1 (0.42) | CYP11B1TDP1GRM2PARP1NPC1 | |
| SCHEMBL20576042 | 0.85 | CYP11B1 (0.41) | CYP11B1TDP1GRM2PARP1NPC1 | |
| SCHEMBL485115 | 0.81 | — | — | |
| SCHEMBL29725206 | 0.81 | — | — | |
| SCHEMBL1585757 | 0.80 | TAAR1 (0.52) | CYP11B1TDP1SMN1; SMN2L3MBTL1KMT2A | |
| SCHEMBL5855 | 0.80 | CYP11B1 (0.43) | CYP11B1GRM2PARP1NPC1NFKB1 | |
| SCHEMBL5628 | 0.80 | CYP11B1 (0.43) | CYP11B1TDP1GRM2PARP1NPC1 | |
| SCHEMBL1874677 | 0.80 | SMN1; SMN2 (0.46) | CYP11B1TDP1GRM2NPC1NFKB1 | |
| SCHEMBL2094576 | 0.80 | CYP11B1 (0.43) | CYP11B1GRM2PARP1NPC1NFKB1 | |
| SCHEMBL12854771 | 0.78 | MAOA (0.45) | CYP11B1TDP1GRM2TRPV6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-105377857-A | Novel azabenzimidazole derivatives | BOEHRINGER INGELHEIM INT | 2016-03-02 | — | — | CN | disclosed |
| CN-102666541-B | Purine or deazapurine derivatives for the treatment of, in particular, viral infections | GILEAD SCIENCES, INC. (US) | 2015-11-25 | — | — | CN | disclosed |
| US-8906852-B2 | Inhibitors of protein tyrosine kinase activity | METHYLGENE INC. (CA) | 2014-12-09 | — | — | US | disclosed |
| US-8906852-B2 | Inhibitors of protein tyrosine kinase activity | METHYLGENE INC. (CA) | 2014-12-09 | — | — | US | disclosed |
| US-8906852-B2 | Inhibitors of protein tyrosine kinase activity | METHYLGENE INC. (CA) | 2014-12-09 | — | — | US | disclosed |
| CN-102427853-B | Protease Inhibitors | ORION CORP | 2014-11-05 | — | — | CN | disclosed |
| US-20140315801-A1 | METHODS OF TREATMENT OF CELL PROLIFERATIVE AND/OR OPHTHALMIC DISEASES, DISORDERS AND CONDITIONS USING INHIBITORS OF PROTEIN TYROSINE KINASE ACTIVITY | METHYLGENE INC (CA) | 2014-10-23 | — | — | US | disclosed |
| US-20140315801-A1 | METHODS OF TREATMENT OF CELL PROLIFERATIVE AND/OR OPHTHALMIC DISEASES, DISORDERS AND CONDITIONS USING INHIBITORS OF PROTEIN TYROSINE KINASE ACTIVITY | METHYLGENE INC (CA) | 2014-10-23 | — | — | US | disclosed |
| US-20140315801-A1 | METHODS OF TREATMENT OF CELL PROLIFERATIVE AND/OR OPHTHALMIC DISEASES, DISORDERS AND CONDITIONS USING INHIBITORS OF PROTEIN TYROSINE KINASE ACTIVITY | METHYLGENE INC (CA) | 2014-10-23 | — | — | US | disclosed |
| CN-103596951-A | 8-ethyl-6-(aryl)pyrido [2,3-d]pyrimidin-7(8h)-ones for the treatment of nervous system disorders and cancer | AFRAXIS INC | 2014-02-19 | — | — | CN | disclosed |
| CN-101228115-A | Bis-aromatic amides and their uses as sweet flavor modifiers, tastants and taste enhancers | SENOMYX INC (US) | 2008-07-23 | — | — | CN | disclosed |
| CN-101094830-A | Fused bicyclic carboxamide derivatives for use as CXCR2 inhibitors in the treatment of inflammation | SANOFI AVENTIS DEUTSCHLAND (DE) | 2007-12-26 | — | — | CN | disclosed |
| CN-100343233-C | Malononitrile compounds and their use | SUMITOMO CHEMICAL CO (JP) | 2007-10-17 | — | — | CN | disclosed |
| CN-101010339-A | Human glucagon-like-peptide-1 modulators and their use in treatment of diabetes and related conditions | BRISTOL MYERS SQUIBB CO (US) | 2007-08-01 | — | — | CN | disclosed |
| CN-1863779-A | Novel indazole derivative | UBE INDUSTRIES (JP) | 2006-11-15 | — | — | CN | disclosed |
| CN-1805943-A | Alpha substituted carboxylic acid as PPAR modulators | PFIZER (US) | 2006-07-19 | — | — | CN | disclosed |
| CN-1741994-A | 3-aminopyrrolidine derivatives as modulators of chemokine receptors | INCYTE CORP (US) | 2006-03-01 | — | — | CN | disclosed |
| CN-1419545-A | 3-cyanoquinolines, 3-cyano-1,6-naphthyridines, and 3-cyano-1,7-naphthyridines as protein kinase inhibitors | WYETH CORP (US) | 2003-05-21 | — | — | CN | disclosed |
| CN-1039228-C | Novel substituted tert-amino compund | YAMANOUCHI PHARMA CO LTD (JP) | 1998-07-22 | — | — | CN | disclosed |
| CN-1079962-A | New substituted tertiary amine compound and salt thereof | YAMANOUCHI PHARMA CO LTD (JP) | 1993-12-29 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140315801-A1 | METHODS OF TREATMENT OF CELL PROLIFERATIVE AND/OR OPHTHALMIC DISEASES, DISORDERS AND CONDITIONS USING INHIBITORS OF PROTEIN TYROSINE KINASE ACTIVITY | FLT1, KDR, FLT4 | CYP11B1 2901/4885TDP1 934/4885GRM2 3266/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.